Matthew D. Snape, MBBS, MD, FRCPCH, FPM, FMedSci

Vice President, Clinical Development, Pediatric and Maternal Vaccines
Moderna Biotech UK, Inc
Didcot, England, United Kingdom

In 2022 I joined Moderna UK in a global role as Vice President, Clinical Development of Maternal and Paediatric Vaccines, where I am primarily working on the development of vaccines against Respiratory Syncytial Virus (RSV).

Prior to this I was Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group, University of Oxford, where I had worked since 2003, combining oversight of clinical trials of vaccines against Ebola Virus, meningococcus, pneumococcus, RSV, Influenza and SARS-CoV-2 with clinical work as a general paediatrician. From 2017 until 2022 I was the director of the NIHR funded National Immunisation Schedule Evaluation Consortium (NISEC), which led the studies of mixed COVID-19 vaccine schedules (Com-Cov, COV-Boost, Com-Flu-Cov)

Disclosure(s): Moderna, Inc.: Emplolyee, Stocks/Bonds (Public Company)

Presentation(s):

• 168 - Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an Investigational Respiratory Syncytial Virus Vaccine, in Participants Aged 2 to < 18 Years at High Risk of Severe Disease

  Thursday, October 17, 2024
  2:33 PM – 2:45 PM US PT